Optimized Anti-CD3 Variable Regions for Bispecific Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-based therapeutics face challenges in enhancing clinical efficacy, particularly in achieving monovalent binding to antigens, which is crucial for specific immune responses without triggering undesired toxicities.
Innovation Solution
Development of optimized anti-CD3 variable sequences for use in bispecific formats, including scFv components, to achieve monovalent binding and improved stability, with specific amino acid substitutions and Fc region modifications to alter binding properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bivalent binding is used in antibody-based therapeutics, then binding affinity to antigens is improved, but undesired toxicities are triggered due to excessive immune activation
Solution Approach 1:
The antibody is divided into separate functional modules: a bivalent Fc region for high-affinity antigen binding and monovalent scFv regions for specific immune engagement. This segmentation allows each region to perform its optimized function independently, achieving both high binding affinity and controlled immune activation.
Solution Approach 2:
Different regions of the antibody are assigned different binding valencies and functional properties. The Fc region is engineered for bivalent binding to provide strong antigen capture, while the scFv regions are designed for monovalent binding to enable precise immune cell activation without excessive cross-linking and toxicity.
2Reliability
If antibody fragments are used to achieve monovalent binding, then specificity is improved, but stability and half-life are reduced
Solution Approach 1:
The patent combines antibody fragments (scFv regions) with full-length antibody components (Fc region) into a hybrid construct. The scFv regions provide monovalent binding specificity, while the Fc region provides stability, long half-life through FcRn recycling, and bivalent binding capability. This merging allows the molecule to simultaneously exhibit properties of both fragments and full antibodies.
3Duration of action of stationary object
If full-length antibodies are used to improve stability, then half-life is extended, but monovalent binding capability is lost
Solution Approach 1:
The antibody construct is designed with dynamic flexibility in its binding regions. The scFv domains can independently engage antigens in a monovalent manner when needed for specific immune activation, while the Fc region maintains its bivalent structure for stable antigen capture and extended half-life. This dynamic design allows the molecule to adapt its binding mode based on the functional requirements of different immune responses.
Data Source
AI summary
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.